Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals.
Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals.
复制标题
DOI：
10.1002/jia2.25032
复制
发表时间：
2018-03
影响因子：
6
通讯作者：
HIV-BResNet
中科院分区：
文献类型：
--
作者：
Arruda MB;Boullosa LT;Cardoso CC;da Costa CM;Alves CR;de Lima ST;Kaminski HT;Aleixo AW;Esposito AO;Cavalcanti AM;Riedel M;Couto-Fernandez JC;Ferreira SB;de Oliveira IC;Portal LE;Wolf HH;Fernandes SB;de M C Pardini MI;Feiteiro MV;Tolentino FM;Diaz RS;Lopes GI;Francisco RB;Véras NM;Pires AF;Franchini M;Mesquita F;Tanuri A;HIV-BResNet
在巴西，目前有487 450多人正在接受抗逆转录病毒治疗。为了监测耐药菌株在该国的传播和艾滋病毒亚型分布，这项工作旨在估计其流行率，并描述2013年至2015年期间最近被诊断为艾滋病毒的个人的全国治疗前耐药性。使用针对近期诊断为HIV的抗逆转录病毒初治个体的HIV阈值调查方法（HIV‐THS，WHO），从巴西所有五个大区域的51个人口稠密城市中选择受试者。通过基因组测序进行HIV pol基因型检测。我们分析了来自1568名最近被诊断为HIV的抗逆转录病毒初治个体的样本，总体传播耐药性（TDR）患病率为9.5%（150个序列）。根据巴西的地理区域，耐药的区域流行率在东北部为9.4%，东南部为11.2%，中部为6.8%，北部为10.2%，南部为8.8%。核苷类逆转录酶抑制剂（NRTI）的抑制剂特异性TDR患病率为3.6%，非核苷类逆转录酶抑制剂（NNRTI）为5.8%，蛋白酶抑制剂（PI）为1.6%; 1.0%的个体对一种以上的抑制剂耐药。总体而言，亚型B在每个地区都更普遍，但南部除外，那里亚型C占主导地位。据我们所知，这是在巴西进行的第一次全国代表性抽样的热带雨林研究。在巴西的五个地理区域中，TDR流行率显示为中等水平，尽管有些城市的TDR流行率较高，例如圣保罗达到14%。这些结果进一步说明了监测研究的重要性，以设计未来的战略，在初级抗逆转录病毒治疗，旨在减轻TDR，以及预测未来的趋势，在其他地区的地球仪的大规模抗逆转录病毒（ARV）治疗的实施。
In Brazil, more than 487,450 individuals are currently undergoing antiretroviral treatment. In order to monitor the transmission of drug‐resistant strains and HIV subtype distribution in the country, this work aimed to estimate its prevalence and to characterize the nationwide pretreatment drug resistance in individuals recently diagnosed with HIV between 2013 and 2015. The HIV threshold survey methodology (HIV‐THS, WHO) targeting antiretroviral‐naive individuals with recent HIV diagnosis was utilized, and subjects were selected from 51 highly populated cities in all five Brazilian macroregions. The HIV pol genotypic test was performed by genomic sequencing. We analysed samples from 1568 antiretroviral‐naive individuals recently diagnosed with HIV, and the overall transmitted drug resistance (TDR) prevalence was 9.5% (150 sequences). The regional prevalence of resistance according to Brazilian geographical regions was 9.4% in the northeast, 11.2% in the southeast, 6.8% in the central region, 10.2% in the north and 8.8% in the south. The inhibitor‐specific TDR prevalence was 3.6% for nucleoside reverse transcriptase inhibitors (NRTIs), 5.8% for non‐nucleoside reverse transcriptase inhibitors (NNRTIs) and 1.6% for protease inhibitors (PIs); 1.0% of individuals presented resistance to more than one class of inhibitors. Overall, subtype B was more prevalent in every region except for the southern, where subtype C prevails. To the best of our knowledge, this is the first TDR study conducted in Brazil with nationwide representative sampling. The TDR prevalence revealed a moderate rate in the five Brazilian geographical regions, although some cities presented higher TDR prevalence rates, reaching 14% in São Paulo, for example. These results further illustrate the importance of surveillance studies for designing future strategies in primary antiretroviral therapy, aiming to mitigate TDR, as well as for predicting future trends in other regions of the globe where mass antiretroviral (ARV) treatment was implemented.
登录
查看更多内容
影响因子：
3.2
作者：
Pennings PS
通讯作者：
Pennings PS
影响因子：
3.7
作者：
Karlsson A;Björkman P;Bratt G;Ekvall H;Gisslén M;Sönnerborg A;Mild M;Albert J
通讯作者：
Albert J
影响因子：
3.8
作者：
Bello, Gonzalo;Passaes, Caroline P. B.;Morgado, Mariza G.
通讯作者：
Morgado, Mariza G.
影响因子：
3.2
作者：
Bittencourt Passaes, Caroline Pereira;Bello, Gonzalo;Guimares, Monick Lindenmeyer
通讯作者：
Guimares, Monick Lindenmeyer
影响因子：
6
作者：
de Moraes Soares, Celina M. P.;Vergara, Tania R. C.;Diaz, Ricardo S.
通讯作者：
Diaz, Ricardo S.